Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
NSE’s offer for sale covers up to 126,436,650 shares, with all proceeds paid to selling shareholders after their expenses and applicable taxes.
NSE IPO retains a 49% ceiling on all foreign ownership, while 2026 resolutions raised the aggregate NRI and OCI investment limit from 10% to 24%.
National Stock Exchange separated critical operations from regulatory-risk oversight in May 2026, with seven Public Interest Directors on its 12-member Governing Board.
JSW Infrastructure is drawing trader attention as it trades near the ₹355 area, with social media tracking key supports, pivots, and momentum readings.
NSE’s equity-options premium market share fell 28.38 percentage points from 96.86% in Fiscal 2024 to 68.48% in the June 2026 quarter.
NSE derived Rs 9,997.568 crore from equity-options fees in FY26, equal to 76.6% of transaction charges and 60.2% of operating revenue.
National Stock Exchange of India operates in a market where 39.30 billion H1CY2026 options contracts generated US$1,286 billion, one-fifth of US premium turnover.
NSE held 92.99% of India’s Fiscal 2026 cash-market turnover and 99.79% of equity-futures turnover, processing Rs 393.82 lakh crore in futures.
NSE has no identifiable promoter, while 3,379 trading members and their associates hold 32.50% of its 247.50 crore pre-offer equity shares.
NSE faces a stayed Rs 856.99 crore compensation claim with 18% annual interest sought, while its Rs 35.5 crore CCI penalty recovery remains stayed.
NSE options generated 60.22% of Fiscal 2026 operating revenue, while transaction charges fell 4.24% after SEBI derivatives measures reduced average daily trading volumes.
NSE paid Rs 1,491.207 crore to SEBI on July 31, 2026 for two co-location matters, while one court closure and one settlement order remain pending.
NSE options generated Rs 9,998 crore, or 60.2%, of Fiscal 2026 operating revenue of Rs 16,601 crore, underscoring transaction-fee concentration.
FSSAI-AYUSH dual compliance raises nutraceutical entry barriers through licensing, GMP and claim requirements as India’s Ayurvedic products market is projected to grow 19.3% annually to 2028.
Himalaya's top 10 suppliers accounted for 94.30% of fiscal 2026 purchases, while its top 10 customers generated 81.24% of revenue without long-term agreements.
Himalaya Nutraveds had Rs 5.32 crore in borrowings on August 14, 2026, including Rs 4.82 crore, or 90.6%, in ICICI cash credit.